Apurvasena Parikh

600 total citations
37 papers, 409 citations indexed

About

Apurvasena Parikh is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Apurvasena Parikh has authored 37 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 15 papers in Radiology, Nuclear Medicine and Imaging and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Apurvasena Parikh's work include Monoclonal and Polyclonal Antibodies Research (12 papers), Lung Cancer Treatments and Mutations (11 papers) and CAR-T cell therapy research (10 papers). Apurvasena Parikh is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), Lung Cancer Treatments and Mutations (11 papers) and CAR-T cell therapy research (10 papers). Apurvasena Parikh collaborates with scholars based in United States, France and Japan. Apurvasena Parikh's co-authors include Daniel Morgensztern, Eric Angevin, Karen Kelly, Rebecca S. Heist, John H. Strickler, Monica Motwani, Todd M. Bauer, D. Ross Camidge, Jonathan W. Goldman and Everett E. Vokes and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Apurvasena Parikh

32 papers receiving 398 citations

Peers

Countries citing papers authored by Apurvasena Parikh

Since Specialization

Citations

This map shows the geographic impact of Apurvasena Parikh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Apurvasena Parikh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Apurvasena Parikh more than expected).

Fields of papers citing papers by Apurvasena Parikh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Apurvasena Parikh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Apurvasena Parikh. The network helps show where Apurvasena Parikh may publish in the future.

Co-authorship network of co-authors of Apurvasena Parikh

This figure shows the co-authorship network connecting the top 25 collaborators of Apurvasena Parikh. A scholar is included among the top collaborators of Apurvasena Parikh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Apurvasena Parikh. Apurvasena Parikh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B‐Cell Lymphoma 2025 ·Clinical Pharmacology & Therapeutics ·Tommy Li, Leonid Gibiansky, Apurvasena Parikh, (unknown), Christopher Chiu, Mariana Sacchi, Huaibao Feng, Tahamtan Ahmadi, Manish Gupta, Steven Xu	1
2	1016eTiP A first-in-human phase I study of LY4066434, a potent and orally bioavailable pan-KRAS inhibitor, in KRAS-mutant solid tumors (Trial in Progress) 2025 ·Annals of Oncology ·(unknown), (unknown), (unknown), Takahiko Koyama, Apurvasena Parikh, (unknown), (unknown), Rachel Galot, Ju Hee Lee, (unknown), Davide Melisi, (unknown), Philippe A. Cassier, Li J, (unknown), Jennifer Wright, (unknown), M. Axelson, Nehal J. Lakhani	0
3	Assessment of Telisotuzumab Vedotin Drug–Drug Interaction Potential Using Physiologically‐Based Pharmacokinetic Modeling and Simulations 2025 ·The Journal of Clinical Pharmacology ·(unknown), (unknown), Rajeev Menon, Patrick Marroum, Apurvasena Parikh	0
4	502LBA LBA Orals: Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors 2024 ·European Journal of Cancer ·(unknown), K. Papadopoulos, (unknown), Apurvasena Parikh, (unknown), (unknown), Alexander Starodub, (unknown), (unknown), (unknown), Wenjing Yu, (unknown), Satwant Lally, Wei Lin, (unknown), (unknown)	1
5	Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma 2024 ·Clinical Pharmacokinetics ·Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Marcel van der Linden, Kinjal Sanghavi, (unknown), Mariana Sacchi, Huaibao Feng, Tahamtan Ahmadi, Manish Gupta, Steven Xu	2
6	O7-4 Phase 1b efficacy of telisotuzumab vedotin and osimertinib in Asian vs non-Asian patients with advanced NSCLC 2023 ·Annals of Oncology ·Hidehito Horinouchi, Jonathan W. Goldman, Byoung Chul Cho, Pascale Tomasini, Martin Dunbar, David Hoffman, Apurvasena Parikh, Vincent Blot, D. Ross Camidge	1
7	1079TiP A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies 2023 ·Annals of Oncology ·Shiraj Sen, Alexander I. Spira, David Sommerhalder, Funda Meric‐Bernstam, Vivek Subbiah, Jordan Berlin, Apurvasena Parikh, Michael Cecchini, Rachel E. Sanborn, (unknown), (unknown), (unknown), (unknown), Guy T. Clifton, Joseph P. Eder, A. W. Tolcher	2
8	Population Pharmacokinetics of Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 2023 ·Blood ·Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Marcel van der Linden, Kinjal Sanghavi, (unknown), Mariana Sacchi, Huaibao Feng, Tahamtan Ahmadi, Manish Gupta, Steven Xu	1
9	Identification of Optimal Dosing Regimen for Subcutaneous Epcoritamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 2023 ·Blood ·Tommy Li, Leonid Gibiansky, Apurvasena Parikh, (unknown), Mariana Sacchi, Huaibao Feng, (unknown), Manish Gupta, Steven Xu	3
10	Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer 2022 ·Journal of Clinical Oncology ·D. Ross Camidge, Fabrice Barlési, Jonathan W. Goldman, Daniel Morgensztern, Rebecca S. Heist, Everett E. Vokes, Alexander I. Spira, Eric Angevin, Wu‐Chou Su, David S. Hong, John H. Strickler, Monica Motwani, Martin Dunbar, Apurvasena Parikh, (unknown), Vincent Blot, Jun Wu, Karen Kelly	68
11	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma 2021 ·Clinical Cancer Research ·D. Ross Camidge, Daniel Morgensztern, Rebecca S. Heist, Minal Barve, Everett E. Vokes, Jonathan W. Goldman, David S. Hong, Todd M. Bauer, John H. Strickler, Eric Angevin, Monica Motwani, Apurvasena Parikh, Zhaowen Sun, Bruce Allen Bach, Jun Wu, Philip Komarnitsky, Karen Kelly	60
12	Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors 2021 ·Cancer Medicine ·Yutaka Fujiwara, Hirotsugu Kenmotsu, Noboru Yamamoto, Toshio Shimizu, Kan Yonemori, Christopher Ocampo, Apurvasena Parikh, Sumiko Okubo, (unknown), Haruyasu Murakami	10
13	A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC 2021 ·JTO Clinical and Research Reports ·D. Ross Camidge, Fabrice Barlési, Jonathan W. Goldman, Daniel Morgensztern, Rebecca S. Heist, Everett E. Vokes, Eric Angevin, David S. Hong, Igor I. Rybkin, Minal Barve, Todd M. Bauer, Angelo Delmonte, Martin Dunbar, Monica Motwani, Apurvasena Parikh, (unknown), Jun Wu, Vincent Blot, Karen Kelly	22
14	P2.01-19 Phase 2 Study of Telisotuzumab Vedotin (Teliso-V) in Previously Treated c-MET+ Non-Small Cell Lung Cancer: Trial in Progress 2019 ·Journal of Thoracic Oncology ·Clara B. Ocampo, Jun Wu, Jyotirmoy Dey, Zhaowen Sun, Mona Motwani, (unknown), Apurvasena Parikh, Jennifer Hay, Philip Komarnitsky, Bruce Allen Bach	3
15	MA14.03 EGFR M+ Subgroup of Phase 1b Study of Telisotuzumab Vedotin (Teliso-V) Plus Erlotinib in c-Met+ Non-Small Cell Lung Cancer 2019 ·Journal of Thoracic Oncology ·D. Ross Camidge, Fabrice Barlési, J M Goldman, Daniel Morgensztern, Rebecca S. Heist, Everett E. Vokes, Alexander I. Spira, Eric Angevin, Wu‐Chou Su, David S. Hong, John H. Strickler, Mona Motwani, Zhaowen Sun, Apurvasena Parikh, Philip Komarnitsky, Jun Wu, Karen Kelly	2
16	Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status. 2019 ·Journal of Clinical Oncology ·D. Ross Camidge, Fabrice Barlési, Jonathan W. Goldman, Daniel Morgensztern, Rebecca S. Heist, Everett E. Vokes, Alexander I. Spira, Eric Angevin, Wu‐Chou Su, David S. Hong, John H. Strickler, Monica Motwani, Zhaowen Sun, Apurvasena Parikh, (unknown), Jun Wu, Karen Kelly	15
17	First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors 2018 ·Journal of Clinical Oncology ·John H. Strickler, Colin D. Weekes, John Nemunaitis, Ramesh K. Ramanathan, Rebecca S. Heist, Daniel Morgensztern, Eric Angevin, Todd M. Bauer, Huibin Yue, Monica Motwani, Apurvasena Parikh, Edward B. Reilly, Daniel Afar, Louie Naumovski, Karen Kelly	104
18	Industry Perspective on Standardizing Food-Effect Studies for New Drug Development 2018 ·Clinical Pharmacokinetics ·Patrick Marroum, Silpa Nuthalapati, Apurvasena Parikh, Mohamad Shebley, David Hoffman, Jiuhong Zha, Amit Khatri, Walid M. Awni	2
19	An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC) 2018 ·Annals of Oncology ·D. Ross Camidge, Rebecca S. Heist, (unknown), Eric Angevin, John H. Strickler, Daniel Morgensztern, Minal Barve, Todd M. Bauer, Everett E. Vokes, (unknown), Mona Motwani, Apurvasena Parikh, Jun Wu, Karen Kelly	3
20	First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors 2016 ·Annals of Oncology ·Eric Angevin, Karen Kelly, Rebecca S. Heist, Daniel Morgensztern, Colin D. Weekes, Todd M. Bauer, Rajesh Ramanathan, John Nemunaitis, Xingwen Fan, (unknown), Apurvasena Parikh, Edward B. Reilly, Daniel Afar, Louie Naumovski, John H. Strickler	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact